Evolving Insights in Blood-Based Liquid Biopsies (CTCs, ctDNA, Exsosomes) for Prostate Cancer Interrogation

A new research perspective was published in Oncoscience (Volume 10) on November 30, 2023, entitled, “Evolving Insights in Blood-Based Liquid Biopsies for Prostate Cancer Interrogation.” During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies. The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. In this new paper, researchers R. Daniel Bonfil, PhD, and Ghaith Al-Eyd, MD, PhD, from Nova Southeastern University discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. 

Login Or Register To Read Full Story